Authors

Latest:

Not All Stage I and II Endometrial Cancers Are Alike

A recent retrospective study found that patients with endometrial cancer in International FICO stage I high- intermediate risk subgroups with fewer than 2 risk factors had a greater than 95% cause-specific survival at 3-year follow-up, and subgroups with 2 or more risk factors had poorer outcomes.

Helen J. Ross, MD

Latest:

Dr. Ross on Toxicity Concerns With Combination Therapies in EGFR+ NSCLC

Helen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.

Francisco Hernandez-Ilizaliturri, MD

Latest:

Dr Hernandez-Ilizaliturri on Immunologic Changes in Venetoclax-Treated CLL

Francisco J. Hernandez-Ilizaliturri, MD, discusses findings from a study investigating immunologic changes in patients with CLL treated with venetoclax.

Manmeet Singh Ahluwalia, MD

Latest:

Dr Ahluwalia on the SURVIVE Trial of SurVaxM Plus Chemoradiation in Newly-Diagnosed Glioblastoma

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses the phase 2b SURVIVE trial of SurVaxM plus chemoradiation in newly-diagnosed glioblastoma.

Saad Z. Usmani, MD, Atrium Health

Latest:

Dr. Usmani on the Rapidly Evolving Landscape in Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, discusses the rapidly evolving treatment landscape in multiple myeloma.

Tae Min Kim, MD, PhD

Latest:

Dr Kim on The Efficacy and Safety of Odronextamab in R/R MZL

Tae Min Kim, MD, PhD, discusses the efficacy of odronextamab monotherapy in patients with relapsed/refractory marginal zone lymphoma.

Hans Lee, MD

Latest:

Dr Lee on the Rationale for Investigating Linvoseltamab in R/R Multiple Myeloma

Hans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Kerry R. Schaffer, MD

Latest:

New Framework for Genetic Testing in Prostate Cancer Takes Shape

In recent years, great progress has been made in understanding the genetics of metastatic prostate cancer which has translated into the development of new precision therapies.

University of Iowa Holden Comprehensive Cancer Center

Latest:

New Breast Center at UI Health Care Aims to Ease the Cancer Journey for Patients

The new breast center at UI Holden Comprehensive Cancer Center aims to make the cancer journey easier and less stressful for patients by providing access to the state's most advanced cancer services in 1 convenient location.

Erin Cobain, MD

Latest:

Dr Cobain on the Importance of Molecular Testing in Metastatic Breast Cancer

Erin Frances Cobain, MD, discusses the importance of molecular testing in patients with metastatic breast cancer.

Julia Foldi, MD, PhD

Latest:

Dr Foldi on T-DXd and Sacituzumab Govitecan in Metastatic Breast Cancer

Julia Foldi, MD, PhD, discusses the utility of of T-DXd and sacituzumab govitecan in the treatment of metastatic HER2-low and triple-negative breast cancer.

Ramez Kouzy, MD

Latest:

Dr Kouzy on the Creation of a Centralized Resource to Inform AI Use in Radiation Oncology

Ramez Kouzy, MD, discusses efforts to improve knowledge of the use of AI in radiation oncology through the creation of an online repository.

Benjamin Solomon, MBBS, PhD, FRACP

Latest:

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLC

Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Haris Ali, MD, City of Hope

Latest:

Multidisciplinary Approaches to GVHD

Medical experts discuss multidisciplinary approaches to GVHD.

Razane El Hajj Chehade, MD

Latest:

Dr Hajj Chehade on Potential Risk Factors for irAE Development in mRCC

Razane El Hajj Chehade, MD, discusses the association between different histologic subtypes in renal cell carcinoma and the risk of developing immune-related adverse effects.

Jill Gilbert, MD

Latest:

A Chance to Choose Your Own Oncology Fellows Content Adventure

Participate in the following brief inventory of relevant topics to let us know what topics you want to see explored by Oncology Fellows.

Marina Baretti, MD

Latest:

Dr Baretti on Entinostat Plus Nivolumab in Advanced PDAC

Marina Baretti, MD, on results from a phase 2 study of entinostat in combination with nivolumab for the treatment of advanced pancreatic ductal adenocarcinoma.

Thorvardur Halfdanarson, MD

Latest:

Dr. Halfdanarson on the Evolving Role of Immunotherapy in CRC

Thorvardur Halfdanarson, MD, discusses the evolving role of immunotherapy in colorectal cancer.

Tycel Phillips, MD

Latest:

Dr Phillips on the Evolution of BTK Inhibitors in MCL

Tycel Phillips, MD, discusses the evolution of treatment with BTK inhibitors for patients with mantle cell lymphoma.

Dae Won Kim, MD

Latest:

Dr Kim on the Addition of NALIRIFOX to the Pancreatic Cancer Treatment Paradigm

Dae Won Kim, MD, discusses findings from the NAPOLI 3 trial that support the use of NALIRIFOX in patients with metastatic pancreatic cancer.